HERNDON, VA — (Marketwire) — 03/24/11 — Signature Mapping Medical Sciences Inc.’s TBDx Tuberculosis (TB) diagnostic system is in the final stages of an independently controlled clinical trial, which is nested as a sub-study to the large international Thibela TB study trial being conducted by the Aurum Institute. Aurum provided a detailed progress update to Signature Mapping and its parent company Applied Visual Sciences, Inc. (OTCBB: APVS). The full update is available at http://www.appliedVS.com.
Key points of the study currently underway are:
- Performance of the TBDx system to date indicates that it performs best as an expert Decision Support System (DSS) to complement expertly trained digital microscopists, offering as additional benefits advances in productivity and lower costs of diagnosis.
- A protocol change to accommodate the DSS approach to the use of TBDx, as well as requests from end-user test experts was approved and the study has recommenced.
- Preliminary results suggest that TBDx may well be best placed as a ‘front-end’ screening technology before the use of newer but more expensive diagnostic technologies.
- The study sample size was reduced to 1000 slides (from 2400) to speed up time to results and costs of processing.
- A routine high-volume laboratory demonstration project protocol has already been developed to follow on from the main scientific study pending results from this study.
- The results of the study are expected to start rolling out in April 2011.
- If successful, this will be the world’s first fully automatic TB diagnostic microscopy system and will establish the underlying Signature Mapping technology as a valid platform on which to develop a host of other image based disease diagnostics.